Renal Cell Cancer Trials

PCYC-1128-CA

PCYC-1128-CA – A phase 1b/2 study of Ibrutinib combination therapy in selected advanced gastrointestinal and genitourinary tumors (bladder, colon, gastric, renal)

1. What type of cancer? What stage?
   1. Advanced GU cancer – bladder and renal
2. Who is eligible?
   1. Advanced GU cancer – bladder and renal
3. How will I be treated?
   1. Advanced GU cancer – bladder and renal

EA8143

EA8143 – A phase III randomized study comparing Perioperative Nivolumab cs observation in patients with localized renal cell carcinoma undergoing nephrectomy.

1. What type of cancer? What stage?
   1. Renal cell cancer
2. Who is eligible?
   1. Patients who are to have surgery – disease localized to kidney
3. How will I be treated?
   1. Nivolumab, an immunotherapy with success in lung and other cancers

CX-839-008

CX-839-008 – A phase III, randomized, placebo controlled study of Atezolizumab (Anti-PD-L1 antibody) as monotherapy and in combination with platinum chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma

1. What type of cancer? What stage?
   1. Renal cell cancer
2. Who is eligible?
   1. Patients with disease progression after first-line therapy
3. How will I be treated?
   1. Adds CB-839 (a drug that inhibits tumor cell nutrient uptake) to treated with Cabozantinib (a small molecule tyrosine kinase inhibitor)

For physicians: more information about this specific trial at clinicaltrials.gov.